Abstract: The European Progestogen Club (EPC) was founded in 1996. The 12th working session of the EPC was held in conjunction with the 8th European Congress on the Menopause (EMAS) in London on 21 May 2009. The main topics presented in this issue are based upon the progestogen, dydrogesterone. This molecule is, compared to natural progesterone, 10–20 times more potent, since all the metabolites of dydrogesterone do not lose their progestogenic activity in contrast to progesterone. Dydrogesterone is, compared with other progestogens, devoid of estrogenic, androgenic and glucocorticoid activity. Also dydrogesterone cannot be converted to estrogens like the 19-nortestosterone derivatives. Overall, it does not exhibit unwanted metabolic side effects. Therefore, dydrogesterone is a suitable progestogen to be used clinically throughout a women's life time both during and outside pregnancy.
Publication Year: 2009
Publication Date: 2009-09-25
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 8
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot